Given the important roles of TGFB ligands and IFN-γ released by immune cells in the TME as related to IDH mutational status, we tested the clinical prognostic significance of high tumor TGFB2 and IFNGR2 mRNA levels measured in low-grade gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.